FOLH1 and posterior cortical atrophy: PSMA PET is particularly valuable for cases of newly diagnosed PCa with unfavorable intermediate or high risk, PSA persistence or rise after surgery or radiotherapy, and non-metastatic castration-resistant prostate cancer identified via conventional imaging 9-11.